|
See related Elaprase inj information |
|
|
|
製造商 |
Shire |
|
代理/經銷商 |
Shire |
|
成份 |
Idursulfase |
|
適應症 |
Long term enzyme replacement therapy for patients with MPS II (Hunter Syndrome). |
|
用量 |
0.5 mg/kg by IV infusion over 1-8 hr wkly. |
|
美國食品藥物管理局之懷孕等級 |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
注意事項 |
Anaphylactic & allergic reactions. Postpone administration in acute respiratory &/or febrile illness. Children < 5 years, elderly. Pregnancy & lactation. |
|
不良反應 |
Anaphylactic & allergic reactions, hypoxic episodes, headache, fever, rash, pruritus, erythema, urticaria, HTN, arthralgia.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Elaprase 注射劑 |
|
Elaprase 2 mg/1 mL x 3 mL |
|
|
|
Manufacturer: |
Shire |
|
Distributor: |
Shire
|
|
|
|
